Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Article Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Article Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Up Front MattersEditorials
You have accessRestricted Access

Heme Oxygenase-1 Gene Polymorphisms—Toward Precision Medicine for AKI

Lisa M. Curtis and Anupam Agarwal
JASN November 2016, 27 (11) 3229-3231; DOI: https://doi.org/10.1681/ASN.2016060699
Lisa M. Curtis
Division of Nephrology, Nephrology Research and Training Center, Birmingham Veterans Administration Medical Center, University of Alabama at Birmingham, Birmingham, Alabama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anupam Agarwal
Division of Nephrology, Nephrology Research and Training Center, Birmingham Veterans Administration Medical Center, University of Alabama at Birmingham, Birmingham, Alabama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading
  • acute renal failure
  • heme oxygenase
  • gene transcription
  • ischemia-reperfusion
  • polymorphisms
  • reactive oxygen species

Heme oxygenase-1 (HO-1) is a 32-kD microsomal enzyme that serves as the rate-limiting step in the breakdown of heme, releasing iron, carbon monoxide, and biliverdin. Using pharmacologic and genetic approaches, the induction of HO-1 is a protective response in renal and nonrenal settings of tissue injury.1 The mechanisms underlying the protective functions of HO-1 have been ascribed to multiple factors (reviewed by Nath1). HO-1 degrades heme (a potent pro-oxidant) released from destabilization of ubiquitous heme proteins during oxidative stress and can damage key cellular constituents. The enzymatic reaction generates iron, which is rapidly sequestered by ferritin; the latter is coinduced with HO-1, displaying inherent protective properties. The HO system is also a major endogenous source for carbon monoxide, a gas with antiapoptotic, anti-inflammatory, and vasodilatory properties. Biliverdin and its subsequent conversion to bilirubin (by biliverdin reductase) both exhibit potent antioxidant properties and can block lipid peroxidation. Previous work by Nath et al.2 was the first to show the protective biologic function of HO-1 in an animal model of glycerol-induced rhabdomyolysis and AKI. Since these pivotal studies, the HO field has attracted numerous investigators from different disciplines and grown exponentially. HO-1 has been a subject of key reviews and editorials, with several focusing on its importance in the kidney.1,3–5

In this issue of the Journal of the American Society of Nephrology, Leaf et al.6 highlight the importance of an association between genetic polymorphisms in the HO-1 promoter and the risk for developing AKI after major cardiac surgery. The polymorphism pertains to variations in length in a GT repeat region in the proximal promoter of the human HO-1 gene, which typically ranges between 12 and 40. Leaf et al.6 found that longer GT repeats (>27) were associated with an 1.58-fold higher odds of AKI compared with that in patients with shorter repeats (<27). Such purine-pyrimidine repeat sequences are found throughout the human genome and display length polymorphisms to variable degrees. How these sequences regulate gene expression is not entirely clear. It is postulated that regions rich in GT repeats promote Z-DNA conformation and inhibit transcriptional activity.7 Shorter GT repeats (<25–27) are associated with robust HO-1 expression, whereas longer GT repeats (>27) are associated with reduced HO-1 expression. These results have been confirmed in transient transfection assays using HO-1 promoter/luciferase constructs as well as in lymphoblastoid and endothelial cell lines from subjects with short and long alleles.8,9 Although several previous papers have highlighted an association between these length polymorphisms and various diseases, this work is the first to show a positive link to AKI and more importantly, in a relatively large number of white patients undergoing cardiopulmonary bypass surgery and at high risk for AKI.6 Therefore, these studies represent an important advance in the field.

Polymorphisms in the GT repeat region of the HO-1 promoter have been associated with a number of diseases. In relation to kidney disease, such length polymorphisms associate with outcomes in patients with CKD, diabetic kidney disease, arteriovenous fistula maturation, and restenosis and in the setting of renal transplantation, wherein length polymorphisms in the donor kidney determine outcome after transplantation (reviewed in Exner et al.10). A few studies have provided conflicting data with respect to the significance of the association of the GT repeats and disease progression/development.11 However, recent meta-analyses with careful subgroup analyses that have included confounding factors, such as age, sex, race, comorbidities, uniform definitions of disease, and complications, as well as risk factors have clearly underscored the importance of the HO-1 GT repeat polymorphism in multiple diseases.12,13 It would be of interest to extrapolate the results of the work by Leaf et al.6 in other populations of patients with AKI and more importantly, those who progress to CKD or ESRD.

Strengths of the study by Leaf et al.6 include a large patient cohort, with 2377 patients undergoing cardiac surgery with cardiopulmonary bypass, and the detailed subgroup analysis performed by the authors. Studies from animal models have revealed that females are relatively less susceptible to AKI compared with males, findings that have been recently corroborated in humans as well.14 In this study, the authors found a stronger association between the HO-1 promoter polymorphism and risk of AKI in women compared with men, an observation that has not been previously reported. Essentially, women with longer GT repeats lost their tolerance to AKI, suggesting that HO-1 could be a potential determinant of such an effect.

Previous studies have elucidated the deleterious effects of heme, which is highly pro-oxidant and damaging to various cellular organelles, including the cell membrane, mitochondria, cytoskeleton, and the nucleus.15 The authors measured various parameters in plasma of 192 patients and found higher plasma free hemoglobin with each additional L allele, without any significant differences in ferritin, transferrin saturation, and catalytic iron levels. The higher levels of plasma free hemoglobin were associated with worse outcomes in AKI and point to the key role of heme-mediated injury in this setting.

Several questions emerge from these studies and will need additional investigation. (1) Given recent studies that have implicated plasma and urine levels of HO-1 as biomarkers of AKI in both animal models and humans,16 do HO-1 promoter polymorphisms correlate with plasma or urine levels of HO-1 or for that matter, HO enzyme activity in leukocytes in AKI? (2) What is the correlation of other genetic polymorphisms in the HO-1 gene in AKI? Askenazi et al.17 evaluated 117 premature infants for genetic variants in the HO-1 promoter and found that neonates with the TT genotype were less likely to have AKI than those with AA or AT genotype for the T(−413)A single–nucleotide polymorphism. However, they found no association between the number of GT repeats in the HO-1 gene promoter and risk of AKI, although the event rate of AKI was quite low (only 34) in this relatively small cohort of neonates. Another single–nucleotide polymorphism has also been described—G(−1135)A—but has not been studied in the context of AKI (reviewed in Exner et al.10). (3) Other key regulatory regions of the human HO-1 gene include a 220-bp intronic enhancer region that is critical in heme–induced HO-1 expression in vitro and in vivo.18,19 Do genetic variations within this enhancer region that affect HO-1 expression associate with the development of AKI? (4) Multiple studies have highlighted an association of bilirubin levels (unconjugated bilirubin, a product of HO enzyme activity) as a protective factor in cardiovascular and renal diseases (reviewed in Hull and Agarwal20). It would be interesting to see if bilirubin levels correlated in any way with the HO-1 GT repeat polymorphisms in these patients.

In this era of precision medicine, genetic testing as a guide to therapy is becoming a standard of care in oncology and other fields of medicine. Limited advances have been made in the field of AKI. In a recent review, 28 studies examining genetic predisposition to the development and/or outcome of AKI were found to be of inadequate quality, heterogeneous in defining concepts and outcomes, replicated with ambiguous results, and mostly underpowered.21 Most of the genes studied included inflammatory genes (e.g., IL-6, IL-10, and TNF-a), vasomotor genes (e.g., ACE, COMT, PNMT, and eNOS), and others (e.g., HIF-1 and myeloperoxidase). In this regard, the work by Leaf et al.6 fills a major gap in knowledge and represents an important contribution to the field.

Disclosures

None.

Acknowledgments

The authors were supported by National Institutes of Health grant R01DK59600 and National Institutes of Health University of Alabama at Birmingham-University of California, San Diego O’Brien Center for Acute Kidney Injury Research grant P30DK079337 (to A.A.).

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

  • Copyright © 2016 by the American Society of Nephrology

References

  1. ↵
    1. Nath KA
    : Heme oxygenase-1 and acute kidney injury. Curr Opin Nephrol Hypertens 23: 17–24, 2014
    OpenUrlCrossRefPubMed
  2. ↵
    1. Nath KA,
    2. Balla G,
    3. Vercellotti GM,
    4. Balla J,
    5. Jacob HS,
    6. Levitt MD,
    7. Rosenberg ME
    : Induction of heme oxygenase is a rapid, protective response in rhabdomyolysis in the rat. J Clin Invest 90: 267–270, 1992
    OpenUrlCrossRefPubMed
  3. ↵
    1. Kinsey GR
    : Myeloid Cell HO-ming in AKI. J Am Soc Nephrol 26: 2067–2069, 2015
    OpenUrlFREE Full Text
    1. Lever JM,
    2. Boddu R,
    3. George JF,
    4. Agarwal A
    : Heme oxygenase-1 in kidney health and disease. Antioxid Redox Signal 25: 165–183, 2016
    OpenUrlCrossRefPubMed
  4. ↵
    1. Nath KA
    : Human AKI and heme oxygenase-1. J Am Soc Nephrol 23: 971–974, 2012
    OpenUrlFREE Full Text
  5. ↵
    1. Leaf DE,
    2. Body SC,
    3. Muehlschlegel JD,
    4. McMahon GM,
    5. Lichtner P,
    6. Collard CD,
    7. Shernan SK,
    8. Fox AA,
    9. Waikar SS
    : Length polymorphisms in heme oxygenase-1 and AKI after cardiac surgery. J Am Soc Nephrol 27: XXX–XXX, 2016
    OpenUrl
  6. ↵
    1. Rich A,
    2. Zhang S
    : Timeline: Z-DNA: The long road to biological function. Nat Rev Genet 4: 566–572, 2003
    OpenUrlCrossRefPubMed
  7. ↵
    1. Hirai H,
    2. Kubo H,
    3. Yamaya M,
    4. Nakayama K,
    5. Numasaki M,
    6. Kobayashi S,
    7. Suzuki S,
    8. Shibahara S,
    9. Sasaki H
    : Microsatellite polymorphism in heme oxygenase-1 gene promoter is associated with susceptibility to oxidant-induced apoptosis in lymphoblastoid cell lines. Blood 102: 1619–1621, 2003
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Taha H,
    2. Skrzypek K,
    3. Guevara I,
    4. Nigisch A,
    5. Mustafa S,
    6. Grochot-Przeczek A,
    7. Ferdek P,
    8. Was H,
    9. Kotlinowski J,
    10. Kozakowska M,
    11. Balcerczyk A,
    12. Muchova L,
    13. Vitek L,
    14. Weigel G,
    15. Dulak J,
    16. Jozkowicz A
    : Role of heme oxygenase-1 in human endothelial cells: Lesson from the promoter allelic variants. Arterioscler Thromb Vasc Biol 30: 1634–1641, 2010
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Exner M,
    2. Minar E,
    3. Wagner O,
    4. Schillinger M
    : The role of heme oxygenase-1 promoter polymorphisms in human disease. Free Radic Biol Med 37: 1097–1104, 2004
    OpenUrlCrossRefPubMed
  10. ↵
    1. Courtney AE,
    2. McNamee PT,
    3. Middleton D,
    4. Heggarty S,
    5. Patterson CC,
    6. Maxwell AP
    : Association of functional heme oxygenase-1 gene promoter polymorphism with renal transplantation outcomes. Am J Transplant 7: 908–913, 2007
    OpenUrlCrossRefPubMed
  11. ↵
    1. Luo H,
    2. Shao Y,
    3. Yao N,
    4. Chen X,
    5. Hu L,
    6. He T
    : Association of heme oxygenase-1 polymorphisms with cancer risk: A systematic review and meta-analysis. J BUON 20: 1142–1153, 2015
    OpenUrlPubMed
  12. ↵
    1. Qiao H,
    2. Sai X,
    3. Gai L,
    4. Huang G,
    5. Chen X,
    6. Tu X,
    7. Ding Z
    : Association between heme oxygenase 1 gene promoter polymorphisms and susceptibility to coronary artery disease: A HuGE review and meta-analysis. Am J Epidemiol 179: 1039–1048, 2014
    OpenUrlCrossRefPubMed
  13. ↵
    1. Aufhauser DD Jr.,
    2. Wang Z,
    3. Murken DR,
    4. Bhatti TR,
    5. Wang Y,
    6. Ge G,
    7. Redfield RR 3rd,
    8. Abt PL,
    9. Wang L,
    10. Svoronos N,
    11. Thomasson A,
    12. Reese PP,
    13. Hancock WW,
    14. Levine MH
    : Improved renal ischemia tolerance in females influences kidney transplantation outcomes. J Clin Invest 126: 1968–1977, 2016
    OpenUrlCrossRefPubMed
  14. ↵
    1. Tracz MJ,
    2. Alam J,
    3. Nath KA
    : Physiology and pathophysiology of heme: Implications for kidney disease. J Am Soc Nephrol 18: 414–420, 2007
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Zager RA,
    2. Johnson AC,
    3. Becker K
    : Plasma and urinary heme oxygenase-1 in AKI. J Am Soc Nephrol 23: 1048–1057, 2012
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Askenazi DJ,
    2. Halloran B,
    3. Patil N,
    4. Keeling S,
    5. Saeidi B,
    6. Koralkar R,
    7. Ambalavanan N
    : Genetic polymorphisms of heme-oxygenase 1 (HO-1) may impact on acute kidney injury, bronchopulmonary dysplasia, and mortality in premature infants. Pediatr Res 77: 793–798, 2015
    OpenUrlCrossRefPubMed
  17. ↵
    1. Deshane J,
    2. Kim J,
    3. Bolisetty S,
    4. Hock TD,
    5. Hill-Kapturczak N,
    6. Agarwal A
    : Sp1 regulates chromatin looping between an intronic enhancer and distal promoter of the human heme oxygenase-1 gene in renal cells. J Biol Chem 285: 16476–16486, 2010
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Kim J,
    2. Zarjou A,
    3. Traylor AM,
    4. Bolisetty S,
    5. Jaimes EA,
    6. Hull TD,
    7. George JF,
    8. Mikhail FM,
    9. Agarwal A
    : In vivo regulation of the heme oxygenase-1 gene in humanized transgenic mice. Kidney Int 82: 278–291, 2012
    OpenUrlCrossRefPubMed
  19. ↵
    1. Hull TD,
    2. Agarwal A
    : Bilirubin: A potential biomarker and therapeutic target for diabetic nephropathy. Diabetes 63: 2613–2616, 2014
    OpenUrlFREE Full Text
  20. ↵
    1. Vilander LM,
    2. Kaunisto MA,
    3. Pettilä V
    : Genetic predisposition to acute kidney injury--a systematic review. BMC Nephrol 16: 197, 2015
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 27 (11)
Journal of the American Society of Nephrology
Vol. 27, Issue 11
November 2016
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Heme Oxygenase-1 Gene Polymorphisms—Toward Precision Medicine for AKI
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Heme Oxygenase-1 Gene Polymorphisms—Toward Precision Medicine for AKI
Lisa M. Curtis, Anupam Agarwal
JASN Nov 2016, 27 (11) 3229-3231; DOI: 10.1681/ASN.2016060699

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Heme Oxygenase-1 Gene Polymorphisms—Toward Precision Medicine for AKI
Lisa M. Curtis, Anupam Agarwal
JASN Nov 2016, 27 (11) 3229-3231; DOI: 10.1681/ASN.2016060699
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

Up Front Matters

  • Ensuring the Equitable Advancement of American Kidney Health—the Need to Account for Socioeconomic Disparities in the ESRD Treatment Choices Model
  • New ‘Antigens’ in Membranous Nephropathy
  • Animal Model of Pregnancy after Acute Kidney Injury Mirrors the Human Observations
Show more Up Front Matters

Editorials

  • Promoting Equity in Eligibility for Registration on the Kidney Transplantation Waiting List: Looking beyond eGFRcr
  • In Search of the Optimal Target for Phosphate Control: Episode 1
  • Missing Self and DSA—Synergy of Two NK Cell Activation Pathways in Kidney Transplantation
Show more Editorials

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • Length Polymorphisms in Heme Oxygenase-1 and AKI after Cardiac Surgery
  • PubMed
  • Google Scholar

Keywords

  • acute renal failure
  • heme oxygenase
  • gene transcription
  • ischemia-reperfusion
  • polymorphisms
  • reactive oxygen species

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire